,,ii #aagth ,,congress #b;d ,session ,s4 #ejjb ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,september #bi1 #bjbb,mr4 ,paul 7for himself1 ,mr4 ,booker1 ,mr4 ,braun1 ,mr4 ,crapo1 ,mr4 ,marshall1 ,ms4 ,collins1 ,mr4 ,king1 ,mr4 ,padilla1 ,mr4 ,sanders1 ,mr4 ,tuberville1 ,mr4 ,lujn1 and ,mr4 ,scott of ,florida7 introduced the following bill2 which was read twice1 considered1 read the third time1 and passed ,a ,,bill ,to allow for alternatives to animal testing for purposes of drug and biological product applications4 #a4 ,short title ,this ,act may be cited as the ,,fda ,modernization ,act #b4j4 #b4 ,alternatives to animal testing 7a7 ,in general ,section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7 is amended-- 7#a7 in subsection 7i7-- 7,a7 in paragraph 7#a77;,a71 by striking preclinical tests 7including tests on animals7 and inserting nonclinical tests2 and 7,b7 in paragraph 7#b77;,b71 by striking animal and inserting nonclinical tests2 and 7#b7 after subsection 7y71 by inserting the following3 7z7 ,nonclinical test defined ,for purposes of this section1 the term nonclinical test means a test conducted in vitro1 in silico1 or in chemico1 or a non-human in vivo test that occurs before or during the clinical trial phase of the investigation of the safety and effectiveness of a drug1 and may include animal tests1 or non-animal or human biology-based test methods1 such as cell-based assays1 microphysiological systems1 or bioprinted or computer models4 4 7b7 ,biosimilar biological product applications ,item 7bb7 of section #cea7k77#b77;,a77i77,i7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7k77#b77;,a77i77,i77 is amended to read as follows3 7bb7 an assessment of toxicity 7which may rely on1 or consist of1 a study or studies described in item 7aa7 or 7cc772 and 4